Seeking Alpha EN

Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M

Mar 11, 2026 &03381111202631; 20:38 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Foghorn Therapeutics reported Q3 GAAP EPS of -$1.18, missing consensus by $0.08, with revenue of $30.91M falling short of expectations by $0.31M. The company continues to operate at a loss while generating modest revenue, indicating ongoing cash burn concerns.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

FHTX

FHTXStock

Expected to decline

Earnings miss on both EPS and revenue metrics signals operational challenges and potential cash runway concerns for biotech company

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Avoid or reduce exposure to FHTX. Monitor cash position and runway disclosures in upcoming guidance; biotech companies with consistent misses and negative earnings face elevated risk of dilutive financing or strategic alternatives.

KEY SIGNALS

EPS miss of $0.08Revenue miss of $0.31MNegative GAAP earnings (-$1.18)Continued operating lossesCash burn trajectory concern

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 12, 2026 at 00:16 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M

RELATED INTELLIGENCE